Avantor (NYSE:AVTR) Given New $18.00 Price Target at Stifel Nicolaus

Key Points

• Stifel Nicolaus raised Avantor’s price target to $18 from $15 while maintaining a Hold rating, implying about 8.3% upside. Overall analyst sentiment remains Hold, with a consensus target of $14.34.
• Avantor’s latest quarter exceeded expectations, with revenue rising 4.6% year over year to $1.70 billion and adjusted EPS of $0.22 beating estimates by $0.01.
• Shares opened at $16.62 after declining 3%, while institutional investors own approximately 95.1% of the company; Barclays continues to rate the stock Sell with a $15 target.

Avantor (NYSE:AVTR - Get Free Report) had its target price boosted by analysts at Stifel Nicolaus from $15.00 to $18.00 in a research note issued on Thursday, Benzinga reports. The firm currently has a "hold" rating on the stock. Stifel Nicolaus's price objective indicates a potential upside of 8.33% from the stock's current price.

Several other analysts also recently issued reports on AVTR. TD Cowen upped their price objective on shares of Avantor from $15.00 to $17.00 and gave the stock a "hold" rating in a report on Tuesday, October 13th. Citigroup lifted their price objective on Avantor from $9.00 to $11.00 and gave the company a "neutral" rating in a report on Wednesday, July 8th. Evercore set a $17.00 target price on shares of Avantor in a research note on Wednesday. UBS Group assumed coverage on shares of Avantor in a research note on Wednesday, September 9th. They issued a "neutral" rating and a $16.00 target price for the company. Finally, Morgan Stanley boosted their price objective on Avantor from $14.00 to $15.00 and gave the stock an "equal weight" rating in a report on Tuesday, October 13th. Two research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $14.34.

Avantor Trading Down 3.0%

Shares of NYSE:AVTR opened at $16.62 on Thursday. The company has a quick ratio of 1.18, a current ratio of 1.78 and a debt-to-equity ratio of 0.65. Avantor has a 12-month low of $7.26 and a 12-month high of $17.45. The firm has a fifty day moving average of $15.40 and a two-hundred day moving average of $11.20. The firm has a market capitalization of $11.24 billion, a P/E ratio of -19.78, a price-to-earnings-growth ratio of 9.83 and a beta of 0.94.

Avantor (NYSE:AVTR - Get Free Report) last released its quarterly earnings data on Wednesday, October 28th. The company reported $0.22 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.21 by $0.01. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%. The firm had revenue of $1.70 billion during the quarter, compared to analysts' expectations of $1.64 billion. During the same quarter last year, the firm earned $0.22 earnings per share. The business's revenue for the quarter was up 4.6% on a year-over-year basis. On average, equities analysts expect that Avantor will post 0.81 EPS for the current fiscal year.

Institutional Trading of Avantor

A number of large investors have recently added to or reduced their stakes in AVTR. SJS Investment Consulting Inc. boosted its holdings in Avantor by 1,599.7% in the 1st quarter. SJS Investment Consulting Inc. now owns 5,235 shares of the company's stock worth $41,000 after buying an additional 4,927 shares during the period. Elevation Wealth Partners LLC grew its holdings in Avantor by 72.3% during the 3rd quarter. Elevation Wealth Partners LLC now owns 2,803 shares of the company's stock valued at $42,000 after buying an additional 1,176 shares in the last quarter. Root Financial Partners LLC bought a new stake in Avantor in the 3rd quarter worth approximately $57,000. IFP Advisors Inc raised its holdings in shares of Avantor by 901.4% during the 2nd quarter. IFP Advisors Inc now owns 5,858 shares of the company's stock worth $58,000 after acquiring an additional 5,273 shares in the last quarter. Finally, Parallel Advisors LLC boosted its position in shares of Avantor by 21.4% during the 1st quarter. Parallel Advisors LLC now owns 8,452 shares of the company's stock valued at $66,000 after acquiring an additional 1,491 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company's stock.

Avantor News Roundup

Here are the key news stories impacting Avantor this week:

• Positive Sentiment: Avantor reported third-quarter net sales of $1.698 billion, up 4.6% year over year, with organic growth of 5.2%. Revenue exceeded the $1.64 billion consensus estimate, while adjusted EPS of $0.22 topped expectations by $0.01. Avantor Reports Third Quarter 2026 Results
• Positive Sentiment: Both major business segments returned to growth, supporting the company’s outlook and suggesting improving demand across its life sciences and advanced technology markets. Avantor Q3 2026 Earnings: Revenue Beats Estimates as Both Segments Return to Growth
• Positive Sentiment: Management raised its full-year 2026 organic revenue-growth, adjusted EPS and free-cash-flow guidance, a potentially important catalyst for earnings estimates and investor confidence. Avantor Reports Third-Quarter and Nine-Month Results
• Neutral Sentiment: GAAP diluted EPS was $0.30, but the company remained unprofitable on a net-margin basis, which may limit the market’s reaction to the adjusted earnings beat.
• Negative Sentiment: Barclays reiterated a Sell rating and a $15 price target. That target is below the stock’s recent trading range and may reinforce concerns that the shares have moved ahead of near-term fundamentals. Barclays Keeps Sell Rating for Avantor

Avantor Company Profile

Avantor, Inc is a global provider of mission-critical products and services used in the life sciences, healthcare, education, and advanced technology industries. The company supplies chemicals, reagents, laboratory consumables, equipment, and other materials used in research, development, manufacturing, and quality-control activities.

Avantor also provides specialized solutions for biopharmaceutical production, including materials and services that support drug development, biologics manufacturing, and other bioprocessing applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.